The entorhinal cortex (EC) initiates tau pathology in Alzheimer's disease, with grid‑cell layer II neurons showing early vulnerability due to high metabolic demand and low calbindin levels[1][2]. Rapamycin extends lifespan by mimicking caloric restriction through mTORC1 inhibition, which suppresses anabolic growth and activates stress‑response pathways[3][4]. While this intervention improves metabolic and inflammatory profiles, it does not directly clear tau aggregates and may instead exacerbate their accumulation in EC neurons. We hypothesize that chronic mTORC1 suppression forces grid cells into a prolonged low‑energy state that prioritizes survival signaling over protein quality control, thereby increasing the propensity for tau seeding and spread.

Mechanistically, mTORC1 inhibition reduces global protein synthesis but simultaneously upregulates autophagy‑independent salvage pathways and enhances mitochondrial oxidative phosphorylation to maintain ATP under perceived scarcity[3]. In EC layer II stellate and pyramidal cells, which already operate near their bioenergetic limit due to continuous theta‑frequency oscillations[2], this shift creates a mismatch: ATP is redirected to sustain ion‑pumping and oscillatory activity essential for grid firing, while chaperone‑mediated refolding and ubiquitin‑proteasome activity receive fewer resources. Reduced calbindin further impairs calcium buffering, making these neurons more susceptible to activity‑dependent calcium overload that promotes tau hyperphosphorylation[1]. The net effect is a proteostatic bottleneck where misfolded tau escapes degradation, seeds aggregation, and propagates along afferent‑efferent pathways to hippocampal CA1.

This hypothesis generates several testable predictions. First, treating tauopathy mouse models with rapamycin should decrease mTORC1 activity (p‑S6 levels) in EC layer II while increasing markers of mitochondrial stress (e.g., elevated ROS, reduced NAD+/NADH ratio) compared with untreated controls. Second, despite extending median survival, rapamycin‑treated mice will exhibit higher soluble tau oligomer concentrations and lower gridness scores in EC recordings than pair‑fed caloric‑restriction mice, indicating that lifespan benefit correlates with worse spatial coding. Third, pharmacological enhancement of proteostasis in EC—such as overexpression of HSP70 or activation of the unfolded protein response—should rescue rapamycin‑induced tau accumulation without affecting mTORC1 signaling, confirming that the deleterious effect stems from impaired protein quality control rather than mTOR inhibition per se. Finally, immune profiling will reveal that rapamycin’s T‑cell quiescence coincides with reduced microglial phagocytic activity in EC, further limiting tau clearance.

If validated, this hypothesis reframes the longevity signal of mTOR inhibition as a trade‑off: lifespan extension arises from systemic stress adaptation, but at the cost of accelerated neuronal dysfunction in regions whose high activity makes them reliant on robust proteostasis. It suggests that combining rapamycin with agents that bolster EC‑specific protein homeostasis—or timing rapamycin administration to avoid periods of peak grid‑cell activity—could preserve cognitive function while retaining systemic health benefits.